Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 13,782	$ 37,407
Prepaid clinical trial costs	4,889	2,861
Prepaid expenses and other	1,417	1,345
Total current assets	20,748	46,027
Operating right-of-use assets, net	8,131	8,960
Property and equipment, net	5,438	3,692
Deposits and other	1,226	1,505
Total assets	35,543	60,184
Current liabilities:
Operating lease liabilities, current	845	1,011
Accrued compensation and related benefits	1,553	4,133
Accrued clinical trial related costs	4,094	3,773
Accrued expenses and other	1,108	704
Total current liabilities	38,729	29,861
Operating lease liabilities, non-current	8,109	8,755
Other long-term liabilities	119	0
Stockholders’ equity:
Preferred stock, at stated value; 10,000,000 shares authorized, and no shares issued and outstanding at September 30, 2022 and December 31, 2021	0	0
Common stock, $0.001 par value; 600,000,000 shares authorized with 12,933,736 and 9,713,767 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively	13	10
Additional paid-in capital	626,251	599,703
Accumulated deficit	(642,877)	(583,344)
Total stockholders’ equity (deficit)	(16,613)	16,369
Total liabilities and stockholders’ equity	35,543	60,184
Consolidated entity, excluding related party
Current liabilities:
Accounts payable	29,182	15,781
Healios
Current assets:
Accounts receivable from Healios	660	1,414
Unbilled accounts receivable from Healios	0	3,000
Current liabilities:
Accounts payable to Healios	0	1,119
Deferred revenue - Healios	0	3,340
Warrant liability	1,947	0
Advance from Healios	$ 5,199	$ 5,199